Breaking News Instant updates and real-time market news.

SRNE

Sorrento Therapeutics

$1.77

0.08 (4.73%)

10:44
10/09/19
10/09
10:44
10/09/19
10:44

Sorrento Therapeutics announces closing of $25M registered direct offering

Sorrento Therapeutics announced the closing of its previously announced registered direct offering of 10,869,566 shares of its common stock and warrants to purchase up to 10,869,566 shares of its common stock, at a combined purchase price of $2.30 per share and related warrant. The net proceeds to Sorrento from this offering are expected to be approximately $23.3M, after deducting the placement agent's fees and other estimated offering expenses. Sorrento currently intends to use the net proceeds from the offering for the continued clinical development of its RTX and CD38 CAR-T programs and general research and development, working capital and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

SRNE Sorrento Therapeutics
$1.77

0.08 (4.73%)

12/12/18
HCWC
12/12/18
NO CHANGE
HCWC
Buy
Sorrento Therapeutics has multiple catalysts in 2019, says H.C. Wainwright
2019 should represent a turning point for Sorrento Therapeutics, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The analyst believes the company is in position to report "multiple value-driving clinical data catalysts" over the course of 2019, both with its pain management portfolio and its cancer immunotherapy candidates. He thinks the interest in anti-CD38 CAR-T approaches has only increased following the recently concluded American Society for Hematology annual meeting. Further, Sorrento's recent financing transactions "provide a pathway to sustainability," adds Selvaraju. He reiterates a Buy rating on the shares with a $40 price target.
03/20/19
RILY
03/20/19
NO CHANGE
Target $12
RILY
Buy
B. Riley FBR boosts Sorrento target to $12, sees 'numerous' catalysts
B. Riley FBR analyst Andrew D'Silva raised his price target for Sorrento Therapeutics to $12.00 from $10.50 and maintains a Buy rating on the shares following the company's Q4 results. Following the "strong close to 2018," the analyst lowered his cash burn estimates and pushed out projected capital raises. The top- and bottom-line beats were due to higher sales and services revenue, primarily out of Scilex Pharmaceuticals, the company's majority-owned subsidiary, as ZTlido sales were recognized a quarter earlier than expected, D'Silva tells investors in a research note. The analyst, however, continues to believe the primary driving force of Sorrento's share price is "locked in its product pipeline." With "numerous high-value opportunities" that primarily extend across immuno-oncology, pain management, and animal health, D'Silva sees a positive risk/reward on the stock.
07/23/19
HCWC
07/23/19
NO CHANGE
Target $30
HCWC
Buy
Sorrento Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Sorrento Therapeutics to $30 from $40 to reflect dilution from the company's sale of 8.3M shares at $3.00. He views resiniferatoxin as one of the most promising projects in Sorrento's pipeline and reiterates a Buy rating on the shares, however.
10/07/19
JMPS
10/07/19
INITIATION
Target $21
JMPS
Outperform
Sorrento Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis initiated Sorrento Therapeutics with an Outperform rating and a price target of $21. The analyst cites the company's "attractive asset" Resiniferatoxin being ready for Phase 2/3 trials, which is targeting a multi-million patient markets in non-opioid pain therapy. Ellis also points to Sorrento seeking an FDA "breakthrough designation" for total knee arthroplasty deferment which, if granted, will initiate registration trials in Q1 of next year.

TODAY'S FREE FLY STORIES

CE

Celanese

$121.37

-0.3 (-0.25%)

16:37
10/21/19
10/21
16:37
10/21/19
16:37
Hot Stocks
Breaking Hot Stocks news story on Celanese »

Celanese down 2.8% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:36
10/21/19
10/21
16:36
10/21/19
16:36
Earnings
Celanese sees FY20 EPS $11-$12 , consensus $11.25 »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HMST

HomeStreet

$28.66

0.27 (0.95%)

16:36
10/21/19
10/21
16:36
10/21/19
16:36
Hot Stocks
HomeStreet board approves additional share buyback of up to $25M »

HomeStreet said its board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

GME

GameStop

$5.93

-0.02 (-0.34%)

16:35
10/21/19
10/21
16:35
10/21/19
16:35
Conference/Events
GameStop management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

HSTM

HealthStream

$26.33

0.13 (0.50%)

16:35
10/21/19
10/21
16:35
10/21/19
16:35
Earnings
HealthStream sees FY19 revenue $252M-$256M, consensus $255.46M »

Sees FY19 Adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:35
10/21/19
10/21
16:35
10/21/19
16:35
Earnings
Celanese cuts FY19 EPS view to $9.60-$9.80 from 'see path to $10.50' 

Consensus $10.14.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

HMST

HomeStreet

$28.66

0.27 (0.95%)

16:35
10/21/19
10/21
16:35
10/21/19
16:35
Earnings
HomeStreet reports Q3 EPS 54c, consensus 33c »

"Homestreet's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:34
10/21/19
10/21
16:34
10/21/19
16:34
Hot Stocks
Celanese says market conditions unlikely to improve in 2019 »

The company's says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

OSB

Norbord

$26.75

0.36 (1.36%)

16:33
10/21/19
10/21
16:33
10/21/19
16:33
Hot Stocks
Norbord to indefinitely curtail production on Line 1 at Cordele OSB mill »

Nobord announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSTM

HealthStream

$26.33

0.13 (0.50%)

16:33
10/21/19
10/21
16:33
10/21/19
16:33
Earnings
HealthStream reports Q3 EPS 11c, consensus 6c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

UGI

UGI Corporation

$48.25

0.07 (0.15%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Conference/Events
UGI Corporation management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 12

    Nov

BXS

BancorpSouth

$29.66

0.17 (0.58%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Earnings
BancorpSouth reports Q3 net operating EPS 69c, consensus 61c »

Net interest margin -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TD

Toronto-Dominion

$56.80

0.34 (0.60%)

, AMTD

TD Ameritrade

$37.64

0.85 (2.31%)

16:32
10/21/19
10/21
16:32
10/21/19
16:32
Hot Stocks
TD Bank comments on expected impact of TD Ameritrade Q4 earnings »

TD Bank Group (TD)…

TD

Toronto-Dominion

$56.80

0.34 (0.60%)

AMTD

TD Ameritrade

$37.64

0.85 (2.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 27

    Oct

SECO

Seeco Holding

$6.15

0.2 (3.36%)

16:31
10/21/19
10/21
16:31
10/21/19
16:31
Conference/Events
Seeco Holding management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

CE

Celanese

$121.37

-0.3 (-0.25%)

16:31
10/21/19
10/21
16:31
10/21/19
16:31
Earnings
Celanese reports Q3 adjusted EPS $2.53, consensus $2.51 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

OBE

Obsidian Energy

$0.70

(0.00%)

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Hot Stocks
Obsidian Energy CFO David Hendry resigns »

Obsidian Energy said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWAV

ShockWave Medical

$33.98

1.68 (5.20%)

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Initiation
ShockWave Medical initiated  »

ShockWave Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

16:30
10/21/19
10/21
16:30
10/21/19
16:30
Options
Preliminary option volume of 16.2M today »

Preliminary option volume…

TCMD

Tactile Systems

$46.66

-0.42 (-0.89%)

16:29
10/21/19
10/21
16:29
10/21/19
16:29
Initiation
Tactile Systems initiated  »

Tactile Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

SAGE

Sage Therapeutics

$140.90

0.9 (0.64%)

16:29
10/21/19
10/21
16:29
10/21/19
16:29
Conference/Events
Sage Therapeutics management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 12

    Nov

NVRO

Nevro

$85.85

0.88 (1.04%)

16:27
10/21/19
10/21
16:27
10/21/19
16:27
Initiation
Nevro initiated  »

Oppenheimer starts Nevro…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

WSFS

WSFS Financial

$44.14

0.02 (0.05%)

16:26
10/21/19
10/21
16:26
10/21/19
16:26
Earnings
WSFS Financial reports Q3 EPS 98c, consensus 87c »

Net interest income in 3Q…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

QTNT

Quotient

$8.13

-0.33 (-3.90%)

16:25
10/21/19
10/21
16:25
10/21/19
16:25
Conference/Events
Quotient management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 04

    Nov

HXL

Hexcel

$74.60

-1.61 (-2.11%)

, BA

Boeing

$331.09

-13 (-3.78%)

16:25
10/21/19
10/21
16:25
10/21/19
16:25
Hot Stocks
Hexcel CEO sees further uncertainty related to Boeing 737 Max return to service »

CEO Nick Stanage states:…

HXL

Hexcel

$74.60

-1.61 (-2.11%)

BA

Boeing

$331.09

-13 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

XAIR

Beyond Air

$4.32

(0.00%)

16:25
10/21/19
10/21
16:25
10/21/19
16:25
Initiation
Beyond Air initiated  »

Oppenheimer starts Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.